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Summary: For several decades, it has been known that T-cell activation
in vitro leads to increased glycolytic metabolism that fuels proliferation
and effector function. Recently, this simple model has been compli-
cated by the observation that different T-cell subsets differentially regu-
late fundamental metabolic pathways under the control of distinct
molecular regulators. Although the majority of these data have been
generated in vitro, several recent studies have documented the metabo-
lism of T cells activated in vivo. Here, we review the recent data sur-
rounding the differential regulation of metabolism by distinct T-cell
subsets in vitro and in vivo and discuss how differential metabolic regula-
tion might facilitate T-cell function vis-a`-vis proliferation, survival, and
energy production. We further discuss the important therapeutic impli-
cations of differential metabolism across T-cell subsets and review
recent successes in exploiting lymphocyte metabolism to treat
immune-mediated diseases.
Keywords: lymphocyte, metabolism, oxidative phosphorylation, glycolysis, reactive
oxygen species, Bz-423
Classical metabolic model of T-cell activation
In the absence of stimulation, the primary function of T
cells is antigenic surveillance, which requires relatively small
amounts of energy in the form of adenosine triphosphate
(ATP), to support cellular processes such as ion homeostasis
(1, 2). Initial studies in unstimulated rat thymocytes and
lymphocytes suggested that glucose, fatty acid, and gluta-
mine oxidation supply ATP in these cells (3–5). The simul-
taneous measurement of oxygen consumption and lactate
production revealed that unstimulated thymocytes generate
96% of their ATP via oxidative phosphorylation (OXPHOS)
with glycolysis only providing 4% (6). More recent studies
have observed a similar metabolic phenotype in unstimu-
lated mouse and human T cells (7, 8), suggesting that the
dependence on OXPHOS is a generalizable feature of resting
lymphocyte populations (9).
Following activation, cellular responses ensue, including
transcriptional program activation, cytokine synthesis and
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secretion, and rapid proliferation. These functions require
increased ATP and metabolic precursors for biomass synthe-
sis (1, 10). How activated lymphocytes meet these increased
metabolic demands has been an active area of investigation
for nearly 50 years (11). Rat thymocytes activated in vitro for
2–3 days increase rates of glycolysis and lactate production
by 20- to 50-fold compared with unstimulated cells (6, 12,
13). Similar increases in glycolysis are observed when
mouse and human T cells are activated in vitro (7, 8). Inter-
estingly, activated T cells and thymocytes do not increase
tricarboxylic acid (TCA) cycle oxidative activity to nearly the
same extent as glycolysis (6, 13, 14). Rather, the majority
of glucose metabolized is released as lactate (12), with most
of the remainder entering the pentose phosphate cycle
(PPC) (3, 14) or otherwise being incorporated into biomass
(15) (Fig. 1). Removing glucose inhibits T-cell proliferation
and cytokine production, even when other metabolic sub-
strates such as glutamine or fatty acids are present, likely
due to the ability of glucose metabolism to concordantly
generate ATP and NADPH and stabilize anti-apoptotic pro-
teins (8, 16). Although less is known about the metabolism
of activated B cells, they appear to utilize high rates of gly-
colysis much like activated T cells (17).
The increased glycolysis that occurs with the activation of
mouse and human T cells in vitro is accompanied by only a
twofold increase in OXPHOS, as measured by mitochondrial
oxygen consumption (7, 14). This increased OXPHOS is
almost certainly not fueled by fatty acid oxidation (FAO), as
in vitro stimulated mouse T cells decrease palmitate oxidation
up to sevenfold compared with unstimulated T cells (14,
18). Rather, the modest increase in OXPHOS in activated T
cells in vitro is likely fueled by the oxidation of glutamine
in the TCA cycle, which increases fourfold in mitogen-
stimulated rat thymocytes or antibody-stimulated mouse T
cells (12, 14). The importance of glutamine metabolism for
activated T-cell function is emphasized by the observation
that elimination of glutamine from culture media decreases
the proliferation and cytokine production of mitogen-stimu-
lated rat and mouse lymphocytes (19, 20). Interestingly, the
OXPHOS inhibitor myxothiazol does not inhibit prolifera-
tion or cytokine production in human CD4+ T cells stimu-
lated with PMA and ionomycin (21). This observation
suggests that the importance of increased glutaminolysis for
activated T-cell function is due to its ability to facilitate bio-
mass synthesis rather than its ability to fuel oxidative ATP
production (22). However, when glucose is removed from
the media, myxothiazol becomes a potent inhibitor of T-cell
proliferation and cytokine production, suggesting that mito-
chondrial ATP production plays an important role in acti-
vated T-cell function when rates of glycolysis are low (21).
Upregulation of glycolysis in the presence of oxygen has
been termed the Warburg effect or aerobic glycolysis due to
its initial characterization in tumor cells by Otto Warburg in
the early 20th century (10, 23). Aerobic glycolysis is a rela-
tively inefficient pathway to generate ATP from glucose,
as complete oxidation of glucose to CO2 produces at least
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Fig. 1. A simple metabolic model of T-cell activation. Resting T cells (left) take up glucose and secrete lactate at low rates. Their lack of
proliferation coincides with a low rate of biomolecule synthesis. Their metabolic demands are met by a low rate of oxidative phosphorylation
(OXPHOS) fueled by the oxidation of glucose, glutamine, and fatty acids. Activated T cells (right) dramatically upregulate glycolysis and lactate
production. Biomass synthesis is facilitated by the action of the pentose phosphate cycle (PPC) as well as the partial mitochondrial metabolism of
glucose and glutamine. Although OXPHOS is increased, fatty acid oxidation decreases compared with resting T cells. These changes were initially
thought to be primarily due to the CD28-dependent activation of AKT.
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15-fold more ATP than metabolism to lactate (10). How-
ever, many types of proliferating cells rely on aerobic gly-
colysis as, in addition to ATP synthesis, it produces reducing
equivalents for pathways that detoxify oxygen radicals and
provides precursors for biomass synthesis (10, 13, 24).
T-cell activation requires engagement of the T-cell recep-
tor (TCR) and costimulation through CD28. CD28 signaling
activates the kinase AKT (7, 8) (Fig. 1), which was thought
to drive increased glycolysis (1) due to its ability to increase
the expression and surface localization of the glucose trans-
porter GLUT1 (7, 8) and increase the activities of key glyco-
lytic enzymes (25–28). Indeed, inhibiting AKT signaling
with inhibitors of phosphatidylinositol-3-kinase (PI3K) pre-
vents activated T cells from upregulating glycolysis (7). In
other cell types (e.g. adipocytes, fibroblasts, and immortal-
ized lymphoid cells), AKT signaling stimulates OXPHOS
and fatty acid synthesis, two pathways that are increased in
activated T cells (29–32). Hence, increased AKT signaling
could account for many of the metabolic changes observed
in activated T cells in vitro. Signaling through inhibitory
receptors on T cells [programmed death-1 (PD-1) or cyto-
toxic T-lymphocyte antigen-4 (CTLA-4)] decreases AKT
activity and glycolysis (33). Hence, the inverse regulation
of AKT by costimulatory and inhibitory receptors could
explain how T cells match metabolic activity with function
(1).
Expanding the model of T-cell metabolism to account
for specific T-cell subsets
Activated CD4+ T cells and effector CD8+ T cells (so called
because they have been appropriately stimulated to lyse tar-
get cells) both increase glycolysis following activation (7,
16, 34). However, effector CD8+ T cells may not increase
OXPHOS above resting cells (34), which distinguishes them
from activated CD4+ T cells that, as described above,
increase OXPHOS by about twofold (7, 35). Consistent with
their lack of increased OXPHOS, effector CD8+ T cells are
exquisitely sensitive to the availability of glucose: lowering
glucose concentrations from 5 (physiologic) to 0.5 mM
decreases effector CD8+ T-cell proliferation by fourfold
(36) and similar reductions decrease IFN-c production by
80% (37). By contrast, CD4+ T cells maintain their ability
to proliferate and secrete cytokines at low levels of glucose
(7, 8). These results point to metabolic differences
between activated T-cell subsets with this particular exam-
ple suggesting that CD4+ T cells have greater metabolic
flexibility with respect to energy-rich substrates than effec-
tor CD8+ T cells.
Does the difference in substrate dependence manifest as
differences between CD4+ and CD8+ T-cell function? Fol-
lowing pathogen clearance, antigen, costimulatory ligands,
and activating cytokines decrease causing most activated T
cells to decrease glycolysis and undergo apoptosis, while a
small number transition to memory cells (38, 39). In this
process, the activated CD4+ T-cell population size contracts
significantly slower than CD8+ T cells, suggesting that acti-
vated CD4+ T cells have a survival advantage over effector
CD8+ T cells when pro-glycolytic signaling is limited (40,
41). This observation could be due to the ability of CD4+ T
cells to upregulate OXPHOS when glycolysis is limited,
allowing them to survive longer than effector CD8+ cells
that fail to increase OXPHOS.
Interestingly, the forced expression of active AKT pro-
motes growth and survival in CD4+ T cells but not CD8+ T
cells (42–44), suggesting that CD4+ T cells may be more
dependent on AKT for their metabolic phenotype than CD8+
T cells. Indeed, inhibiting AKT in activated murine CD8+ T
cells with a pan-isoform inhibitor does not decrease glucose
uptake but rather decreases the expression of numerous
effector molecules (36). Hence, metabolic differences
between activated CD4+ and effector CD8+ T cells could be
due to distinct roles for AKT in these two cell types.
After activation, CD4+ T cells differentiate into a number
of subtypes: Th1 cells, which promote cell-mediated immu-
nity; Th2 cells, which promote humoral immunity; Th17
cells, which promote mucosal immunity and inflammation;
and regulatory T cells (Tregs), which inhibit immune
responses. Interestingly, relative to unstimulated naive CD4+
T cells, pro-inflammatory Th17 cells utilize higher rates of
glycolysis, whereas anti-inflammatory Tregs increase FAO
(45) (Fig. 2). Increased flux through these pathways pro-
vides an indication of their functional significance, which is
supported by mechanistic experiments. For example, inhibit-
ing glycolysis blocks Th17 cell differentiation in vitro and
decreases disease severity in a Th17-mediated mouse model
of experimental autoimmune encephalitis (EAE) (46). By
contrast, the differentiation of Tregs is inhibited by the FAO
inhibitor etomoxir but stimulated by glycolysis inhibition
with 2-deoxyglucose (2DG) (45, 46).
Given these results, it is reasonable to postulate that the
relative availability of glucose versus fatty acids as sub-
strates within inflammatory microenvironments can control
the nature of the immune response. Such metabolic mic-
roenvironments could provide an autoregulatory mecha-
nism guarding against fulminant inflammatory responses,
as the high consumption of glucose during acute immune
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activation could deplete this substrate, which would
induce Treg differentiation and the downregulation of
inflammation.
The different metabolic patterns adopted by Th17 and
Treg cells suggest differing mechanisms of metabolic regu-
lation. T cells cultured in conditions favoring Th17 differ-
entiation induce hypoxia-inducible factor-1a (HIF-1a) in a
STAT3 (signal transducer and activator of transcription 3)-
dependent fashion and the expression of HIF-1a is
required for the induction of the Th17-defining molecules
RAR-related orphan receptor c (RORc) and IL-17 (47).
These results suggest that the pro-glycolytic effects of HIF-
1a (48) might account for the increased glycolysis
observed in Th17 cells. Indeed, the deletion of HIF-1a
decreases glycolysis by fourfold in Th17 cells (46). Inter-
estingly, HIF-1a shunts glucose-derived carbons away from
the mitochondria by activating lactate dehydrogenase
(LDH) and inhibiting pyruvate dehydrogenase (PDH) (49).
This phenomenon limits biomass synthesis in favor of
non-oxidative ATP production (15), and may contribute to
the ability of Th17 cells to survive in hypoxic environ-
ments. Although its role in Th17 cells is clear, HIF-1a
does not appear to be important for glycolysis in CD4+ or
CD8+ T cells 1 day after activation, but may play a role at
later time points (14, 15), and little is known of its
importance in Th1- or Th2-polarized cells.
Consistent with their dependence on FAO rather than gly-
colysis, the deletion of HIF-1a promotes rather than inhibits
Treg differentiation, likely due to the ability of HIF-1a to
bind to and degrade forkhead box P3 (47). Rather, Tregs
express high levels of phosphorylated AMP-activated protein
kinase (AMPK) (45), which regulates FAO by phosphorylat-
ing and inhibiting acetyl coA carboxylase (50, 51) thereby
activating carnitine palmitoyl transferase 1a, the rate-limiting
step in FAO (52). The importance of AMPK activation for
the Treg lineage is supported by the observation that activat-
ing AMPK with metformin increases Treg differentiation in
vitro, whereas its in vivo administration increases Treg num-
bers in a mouse model of asthma (45). A metabolic pheno-
type favoring FAO suggests that Tregs prioritize oxidative
ATP production over the ability to generate biomass or gen-
erate ATP under hypoxic conditions, which could contribute
to the stability of the Treg population in vivo (53).
Like Tregs and in contrast to effector CD8+ T cells, mem-
ory CD8+ T cells depend on AMPK-mediated FAO to meet
their energetic demands (38, 39). Following clearance of
antigen, growth factor signaling becomes limiting and a
fraction of effector CD8+ T cells transition from a glycolytic
metabolism that favors proliferation and biomass synthesis
to oxidative ATP production that is required for long-term
survival (38). This metabolic transition is stimulated by the
pro-memory cytokine IL-15, which promotes mitochondrial
biogenesis and the expression of CPT1 (39).
The importance of FAO for Tregs and memory CD8+ T
cells has clinical implications. The administration of metfor-
min, which activates AMPK and increases FAO, enhances
memory CD8+ T-cell development after infection (38). Met-
formin also increases Treg responses while decreasing dis-
ease severity in a model of asthma (45). These findings
highlight the potential to regulate metabolism as a therapeu-
tic strategy to direct immune responses during infection,
immunization, or inflammatory disease.
Several other regulators of activated T-cell metabolism
have recently been discovered, although their differential
importance among T-cell subsets remains unclear. In CD4+
T cells, estrogen-related receptor-a (ERR-a) is activated in a
CD28-dependent fashion and is required for both increased
glycolysis and OXPHOS (35). How ERR-a activates glycoly-
sis and OXPHOS remains poorly understood; however, ini-
tial studies suggest that it may function to increase the
activity of PDH (35). Myc becomes activated shortly after
T-cell activation and is associated with the upregulation of
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Fig. 2. Regulation of metabolic pathways in activated T-cell subsets.
Activated CD4+ T cells initially dramatically upregulate glycolysis and
modestly increase oxidative phosphorylation (OXPHOS). These changes
are due to signaling through AKT, Myc, and estrogen-related receptor-
a (ERR-a). Activated CD4+ T cells that differentiate into the Th17
lineage primarily rely on glycolysis that is controlled by hypoxia-
inducible factor-1a (HIF-1a). By contrast, activated CD4+ T cells that
differentiate into Tregs rely on fatty acid oxidation (FAO) under the
control of AMP-activated protein kinase (AMPK). Effector CD8+ T cells
principally upregulate glycolysis under the control of Myc, but other
metabolic regulators remain unknown. Like Tregs, memory CD8+ T
cells principally rely on FAO under the control of AMPK.
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several key glycolytic enzymes including GLUT1, hexoki-
nase, phosphofructokinase, and LDH (14, 54). Myc also
induces glutaminolytic enzymes including glutaminase 2
and the glutamine antiporter CD98 (14). Deletion of Myc
decreases glycolysis and glutaminolysis by nearly fourfold
1 day following T-cell stimulation in vitro (14). The impor-
tance of Myc-induced metabolic changes for activated T-cell
function is emphasized by the observation that deletion of
Myc abrogates the proliferation of both CD4+ and CD8+ T
cells in vitro and in vivo (14). Additionally, the expression of
Myc is necessary for the upregulation of PPC activity in acti-
vated T cells, implicating Myc signaling in the production of
NADPH and biomass synthesis. Importantly, the deletion of
Myc does not affect the expression of activation markers,
suggesting that Myc abrogrates activation-induced metabolic
changes rather than blocking the entire activation signal
(14).
Metabolic characteristics of T cells activated in vivo
Historically, nearly all of the work on lymphocyte metabo-
lism employed primary immune cells cultured in vitro from
several hours to several days, raising the possibility that in vi-
tro culture affects the metabolic responses attributed to lym-
phocyte activation (3, 7, 55). For example, typical nutrient
concentrations in plasma and culture media differ with
respect to glucose (5 versus 10–25 mM) (7, 8, 56), gluta-
mine (0.6 versus 2–4 mM) (57, 58), fatty acids such as ole-
ate and palmitate (2–3 versus <20 lM) (58, 59), and
oxygen (3–5% versus 20%) (60–62), and such differences
in substrates can affect metabolic pathway utilization (7,
15). Indeed, OXPHOS activity in CD4+ T cells and activated
thymocytes changes when glucose levels are altered (6, 7,
21). However in non-lymphoid cells, supplementing culture
media with oleate or palmitate to reach near-physiologic
levels (0.25–0.5 mM) induces enzymes involved in FAO
(63, 64) and decreases glycolysis (65). Finally, mouse T
cells activated in vitro with levels of O2 physiologic in condi-
tions of active inflammation (1.5%) take up more glucose
and secrete more lactate than cells grown under atmospheric
O2 (15). Together, these observations suggest that in vitro
conditions have clear potential to influence lymphocyte
metabolism. Thus, conclusions drawn based on studies
involving protracted culture periods need to be interpreted
within the context of the variables described above.
It is known that the nature and length of antigenic pre-
sentation and signal strength varies between in vitro and
in vivo models (66). Depending on the nature of the antigen,
T-cell activation in vivo occurs with varied levels of chronicity
(days to years), whereas stimulation in most in vitro models
is on the order of hours to days (67, 68). Both CD4+ and
CD8+ T cells downregulate glycolysis as they undergo repet-
itive stimulation in vitro (68), possibly due to decreased
CD28 signaling and increased signaling through CTLA-4 and
PD-1. Because the rate of glucose uptake in an activated T
cell increases as the strength of antigenic stimulus increases
(8), gauging qualitative or quantitative aspects of the metab-
olism of immune cells in vivo based on in vitro models
depends on adequately understanding and controlling anti-
gen affinity, T-cell avidity, and length of stimulation.
Recent developments in measuring oxygen consumption
(69) and cell surface marker-based sorting (39) have facili-
tated studies of T cells activated in vivo. For example, the su-
perantigen staphylococcal entertoxin B (SEB) activates Vb8+
T cells by crosslinking the Vb8 subunit of the TCR directly
to the major histocompatibility complex and activates the
roughly 10% of T cells that are Vb8+ rather than the 1 in
105–106 that recognize an individual antigen (70–72). Two
days following immunization with SEB, purified CD4+ Vb8+
T cells underwent a 15-fold Myc-dependent upregulation of
glycolysis compared with unstimulated CD4+ Vb8+ T cells
(14) (Fig. 3). Although this study did not address the effects
on OXPHOS or any parameters of CD8+ T-cell metabolism,
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Fig. 3. Metabolic parameters of T cells activated in vivo. Effector
CD8+ T cells purified without regard to antigen specificity 6–7 days
after Listeria monocytogenes infection have equivalent rates of oxidative
phosphorylation (OXPHOS) as naive cells, but modestly increase
glycolysis, and no information is available about their antioxidant
levels. Activated Vb8+ CD4+ T cells purified 2 days after staphylococcal
entertoxin B (SEB) immunization increase glycolysis by 15-fold
compared with unstimulated cells, but no information is available
regarding their rate of OXPHOS or antioxidant levels. Proliferating
donor T cells purified 7 days after the initiation of graft-versus-host
disease (GVHD) increase OXPHOS 2.5-fold compared with
unstimulated cells and modestly increase glycolysis. These cells suffer
from the depletion of both glutathione and pyruvate.
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the magnitude of the increase in glycolysis is similar to
what is observed in in vitro models. Indeed, SEB stimulation
shares several key features with in vitro models including a
short time course, rapid clearance of the antigen, and robust
activation of large numbers of T cells (73).
In other studies, a smaller increase in glycolysis was found
activating CD8+ T cells in vivo. Endogenous CD8+ Teff cells
(CD44hiCD62Llo) produced only 50% more lactate than naive
CD8+ T cells (CD44loCD62Lhi) 6–7 days following infection
with an attenuated strain of Listeria monocytogenes (39). Teff cells
did not increase OXPHOS, consistent with in vitro studies (34).
In this experiment, the population of Teff cells analyzed
(CD44hiCD62Llo) was not antigen-specific and likely included
T-cell clones of varying affinity for Listeria as well as bystander
Teff with no relationship to Listeria. Hence, the heteroge-
neously activated Teffs may account for the relatively low rate
of lactate production. In addition, as this analysis was done 6
–7 days after bacterial infection, it is possible that the chro-
nicity of exposure allowed downregulation of glycolysis (68).
Bioenergetic characteristics of disease-causing
lymphocytes
Investigating the metabolism of lymphocytes mediating
inflammatory diseases is challenging because these cells are
very low in number, often cannot be identified directly, and
are difficult to isolate from bystander cells in many disease
models (74). With these limitations, many studies have char-
acterized populations in which most cells are not pathogenic.
Notwithstanding these issues, potential metabolic differ-
ences related to disease have been identified. For example,
peripheral blood T cells isolated from patients with lupus
have 50% more mitochondrial mass than T cells from
healthy volunteers, accompanied by a 20% increase in the
mitochondrial membrane potential (Dwm) (75). These find-
ings are consistent with increased TCA cycle activity and
OXPHOS and are supported by recent results showing that
peripheral blood mononuclear cells (PBMCs) from patients
with active lupus (and rheumatoid arthritis) consume 50%
more O2 than cells from healthy controls (76), and spleen
tissue from mice with active lupus oxidize 40% more glu-
cose in the TCA cycle than control cells (68). These data
suggest that pathogenic lymphocytes upregulate OXPHOS,
but the use of bulk cellular populations limits the conclu-
sions that can be drawn.
In graft-versus-host disease (GVHD), alloreactive donor T
cells proliferate in response to host antigen and mediate a
potentially lethal immune response (77). In contrast to
many autoimmune models, murine transplant models
employing congenic markers and cellular proliferation dyes
allow disease-causing cells to be distinguished and isolated
(67). Using these techniques, we observed that proliferating
alloreactive donor T cells increase OXPHOS 2.5-fold com-
pared with resting T cells 7 days after the initiation of
GVHD (67) (Fig. 3). These GVHD-causing T cells also
increase GLUT1 expression by 50% and lactate production
fourfold in comparison with resting T cells (67), which is
consistent with the increased uptake of a glucose analog
observed in the intestinal tracts of mice and humans
suffering from GVHD (78).
The increase in glycolysis observed in GVHD-causing T
cells is modest compared with the increases seen in SEB-acti-
vated CD4+ T cells in vivo and CD8+ and CD4+ T cells acti-
vated in vitro. Notwithstanding the limitations imposed by
assumptions regarding similar coupling efficiencies between
cellular populations and the potential derivation of lactate
from alternative pathways, the rates of oxygen consumption
and lactate production can be used to estimate the propor-
tion of ATP derived from OXPHOS and aerobic glycolysis,
respectively (79). Such calculations suggest that, unlike T
cells activated in vitro, alloreactive T cells rely primarily on
OXPHOS for their synthesis of ATP (67).
Several questions arise in considering this unusual meta-
bolic phenotype in GVHD-causing T cells. For example, why
is their rate of glycolysis relatively low, and how are the
proliferative demands for substrates necessary for biomass
synthesis met in GVHD-causing T cells? During allogeneic
transplantation, host professional antigen-presenting cells
(APCs) stimulate donor T cells and propagate GVHD (80,
81). As some host APCs are not eliminated during GVHD
(81), this ubiquitous presence of stimulatory alloantigen
could result in the repetitive and chronic stimulation of
GVHD-causing T cells. Recently, chronically stimulated T
cells were observed to have two- to threefold lower rates of
glycolysis than acutely activated controls (68), possibly due
to decreased signaling through CD28 and increased signaling
through PD-1 and CTLA-4 (68). The chronicity of stimula-
tion during GVHD contrasts with activation by SEB, which
falls to sub-stimulatory levels by 14 h after immunization
and is completely cleared by 48 h (73). Hence, the acuity
and rapid antigen clearance of the SEB model coupled with
the time that measurements were made (2 days after SEB
injection) may account for the high rates of glycolysis
observed in activated T cells stimulated in vivo by SEB (14).
The molecular mechanism responsible for relatively low
rates of glycolysis in GVHD-causing T cells remains unclear.
Although increased signaling through PD-1 and CTLA-4
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could play a role, we have found that despite their low rates
of glycolysis, GVHD-causing T cells have high amounts of
phosphorylated AKT at the time points in question (unpub-
lished observations). Hence, signaling through PD-1 or
CTLA-4 would have to be restricting glycolysis in an AKT-
independent fashion. This scenario is most feasible for PD-
1, which exerts its anti-glycolytic effects by inhibiting PI3K,
which affects signaling molecules independent of AKT
including the protein kinase C (PKC) family (33, 36).
Regarding non-AKT regulators of metabolism, little is
known about their activity in GHVD; microarray analysis
has revealed that CD8+ effector T cells in murine GVHD
have decreased levels of c-Myc mRNA compared to naive T
cells (82). Hence, low rates of glycolysis in GVHD-causing
T cells could be related to low activity of Myc. Given that
members of the PKC family are known to regulate Myc lev-
els (83), it is possible that chronic stimulation and activa-
tion of inhibitory receptors (e.g. PD-1) limits glycolysis in
GVHD-causing T cells by inhibiting PKC and restricting Myc
activity.
Proliferating cells must generate carbons precursors,
reducing equivalents (NADPH) and free energy (ATP) to
synthesize biomolecules, such as lipids, that are necessary to
grow and divide. The T cells that cause GVHD rapidly pro-
liferate with only a modest increase in glycolytic metabolism
(67), so how do they supply metabolites necessary for bio-
mass synthesis? GVHD-causing T cells are unlikely to be able
to meet all three bioenergetic demands (NADPH, biomole-
cule precursors and ATP) using only their modest rates of
glycolysis. However, unlike acutely activated T cells, there is
evidence to suggest that GVHD-causing T cells upregulate
FAO, a robust source of ATP (67). Indeed, GVHD-causing T
cells have 10- to 20-fold increased levels of acyl-carnitines,
an intermediate in FAO (67). Hence, GVHD-causing T cells
might preferentially utilize glucose for NADPH and biomol-
ecule precursor formation, while relying on FAO for ATP
production. This hypothesis is especially appealing given the
abundance of free fatty acids in vivo and their low levels in
cell culture models. Further exploration is needed to deter-
mine the role of FAO during GVHD and if the regulators of
FAO, such as AMPK, peroxisomal proliferator-activated recep-
tor alpha (PPARa), and PPAR gamma coactivator-1 (PGC-1)
contribute to the function of GVHD-causing T cells.
How would GVHD-causing T cells adopt this more
efficient utilization of glucose? HIF-1a increases LDH
expression and decreases the activity of PDH, thereby fun-
neling glucose-derived carbons away from mitochondrial
biomolecule synthesis (15). Indeed, the deletion of HIF-1a
in activated T cells lowers lactate production and promotes
glucose-derived carbon entry into the mitochondria for bio-
molecule synthesis (15), thereby facilitating proliferation. A
recent microarray analysis showed that effector CD8+ T cells
in a model of GVHD have threefold more HIF-1a mRNA
than naive T cells (82), which is modest compared with the
15-fold increase in HIF-1a mRNA observed in T cells stimu-
lated by anti-CD3 and anti-CD28 antibodies (84). Although
the regulation of HIF-1a at the protein level cautions against
the over-interpretation of mRNA levels (85, 86), these stud-
ies are consistent with an interpretation in which relatively
low levels of HIF-1a activity allows GVHD-causing T cells to
efficiently use glucose for biomolecule synthesis and prolif-
eration rather than lactate production.
Redox consequences of altered bioenergetics in
disease-causing lymphocytes
Although the mitochondrial electron transport chain (ETC)
primarily functions to generate ATP, it is also the major
source of reactive oxygen species (ROS) in mammalian cells,
as 0.5–3% of the O2 used by the mitochondria is converted
into ROS in the form of O2
 (87, 88). O2
 generation
occurs when single electrons ‘leak’ from reactive intermedi-
ates in the ETC (such as flavin mononucleotide or iron–sul-
fur clusters) and react directly with O2 (89). Furthermore,
as Dwm increases (termed ‘hyperpolarization’), mitochon-
drial ROS production also increases, as hyperpolarization of
Dwm prolongs the half-life of reactive intermediates and
increases the likelihood that electrons react with O2 to form
O2
 (90). Hence, cells increase ROS production as their
utilization of OXPHOS increases.
Given that allo- and auto-reactive lymphocytes primarily
rely on OXPHOS rather than glycolysis, it is not surprising
that these cells exhibit increased ROS production. Indeed,
compared with cells from healthy controls, T cells from
patients with lupus exhibit both hyperpolarization of Dwm
and increased ROS levels (91). Increased ROS production is
also a characteristic of cells isolated from animals undergo-
ing GVHD. Lymphocytes, neutrophils, and red blood cells
from mice 5 weeks after GVHD induction have threefold
higher levels of ROS compared with untreated control mice
(92). Although these studies only examined bulk lympho-
cyte populations, our data indicate that GVHD-causing T
cells also exhibit both hyperpolarization of Dwm and
increased ROS levels (67).
The high rates of glycolysis associated with the Warburg
effect benefit proliferating cells not only by allowing bio-
mass and ATP production but also by facilitating antioxidant
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production (10, 13). Glutathione is the most abundant anti-
oxidant in mammalian cells and the formation of its active,
reduced form requires NADPH (24). Inhibiting glycolysis
with 2DG decreases total glutathione levels by 40% and
induces dose- and time-dependent apoptosis in HeLa cells
(93). This increased apoptosis is reversed by the antioxidant
N-acetylcysteine, suggesting that it is due to increased ROS
formation (93).
In addition to maintaining glutathione levels, glycolysis
directly generates pyruvate, which acts as an antioxidant by
eliminating H2O2 and reducing O2
 production in mitochon-
dria (94). The antioxidant functions of pyruvate are empha-
sized by experiments showing that the addition of pyruvate
(0.1–2 mM) to culture media reduces H2O2-induced apop-
tosis and ROS production in a neuroblastoma cell line (94).
Pyruvate also reduces ROS formation due to ischemia–
reperfusion injury in perfused guinea pig hearts (95). Rates of
glycolysis play an important role in regulating intracellular
pyruvate levels, as increasing the glucose concentration of cell
culture media from 2.5 to 12 mM increases intracellular pyru-
vate levels >10-fold in a pancreatic b-cell line (96).
The relatively low rate of glycolysis in auto- and allo-
reactive lymphocytes suggests that these cells might have
depleted antioxidant levels. Indeed, T cells from patients
with lupus have 30% less reduced glutathione than cells
from healthy controls (91), whereas T cells from MRL/lpr
mice with lupus have fourfold less reduced glutathione than
controls (97). Similarly, GVHD-causing T cells have 25%
less total glutathione and more than 10-fold less pyruvate
than control cells, consistent with their reliance on OXPHOS
rather than aerobic glycolysis (67). Proliferating cells utilize
NADPH for biomass synthesis to facilitate proliferation as
well for reduced glutathione production. The depletion of
glutathione in proliferating GVHD-causing T cells suggests
that these cells might prioritize the ability to proliferate over
the ability to protect themselves against oxidative insult and
allocate NADPH accordingly; however, the mechanisms con-
trolling any such NADPH allocation remain unknown.
In contrast to these results, lymphocytes activated in vitro
increase antioxidant levels, consistent with their high rates of
glycolysis. PBMCs stimulated with mitogens for 2 days dou-
ble their glutathione levels compared with unstimulated cells
(98), and acutely stimulated thymocytes increase glucose-
derived pyruvate by 14-fold (13). Although there is no data
on antioxidant levels in in vivo models of acute T-cell activa-
tion, the high rates of glycolysis observed in T cells activated
by SEB suggests that these cells will avoid antioxidant deple-
tion (14). These data suggest that unlike chronically activated
disease-causing lymphocytes, T cells activated in an acute set-
ting maintain their antioxidant levels, which suggests that
acutely activated lymphocytes will be better able to survive
an oxidative insult than disease-causing cells. Given the role
that ROS play in mediating T-cell contraction and apoptosis
(99), antioxidant depletion in disease-causing lymphocytes
may help limit disease severity and suggests that efforts to
treat autoimmune diseases or GVHD with antioxidants may
be less successful than anticipated (92).
Modulating T-cell metabolism as a therapeutic strategy
If activated T cells uniformly utilized a single metabolic
pathway (e.g. aerobic glycolysis) (Fig. 1), it would be
difficult to exploit this pathway for therapeutic purposes.
Inhibiting glycolysis might not only improve autoimmune
and inflammatory diseases, but also lead to widespread
immunosuppression. Similarly, augmenting lymphocyte gly-
colysis might aid in Treg generation and improve immuni-
zation responses but also promote autoimmunity and
inflammation. Fortunately, individual lymphocyte subsets
differentially utilize metabolic pathways, making activated
lymphocyte metabolism a promising target for selective
immunomodulation.
Activated Th17 T cells preferentially upregulate glycolysis
and the glycolytic inhibitor 2DG decreases IL-17 production
and disease severity in EAE (46). While inhibiting glycolysis
is a promising immunomodulatory strategy and likely spares
FAO-dependent Treg and memory CD8+ cells, there are sev-
eral concerns about undesired side effects. The high rate of
glycolysis observed in CD8+ Teff cells and acutely activated
CD4+ T cells suggests that the inhibition of glycolysis might
be associated with non-specific immunosuppression.
Similarly, agents that inhibit glycolysis might decrease hema-
topoietic differentiation and the reconstitution of the hemato-
poietic system in the setting of bone marrow transplant,
given the high glycolytic activity of hematopoietic stem cells
(HSCs) and proliferating bone marrow cells (67, 100).
The T cells that cause GVHD and the bulk population of
lymphocytes investigated in lupus share several metabolic
features including increased OXPHOS and depleted antioxi-
dants. Like a reliance on glycolysis or FAO, these metabolic
features are potential targets for therapeutic manipulation.
Furthermore, the ability of normal lymphocytes to maintain
their antioxidant levels suggests that such a strategy will
cause minimal immunosuppression.
Bz-423 is a non-anxiolytic 1,4-benzodiazepine that targets
the oligomycin-sensitivity conferring protein subunit of the
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Fig. 4. Mechanism for selective induction of apoptosis in disease-causing lymphocytes by Bz-423. In the mitochondrial electron transport
chain (ETC), complexes I and II accept electrons from NADH and succinate and pass these electrons (gray) to complexes III and IV, where they
are eventually transferred to O2 and form H2O. This process pumps protons (green) into the intermembrane space, and these protons flow
through complex V to generate ATP. Electrons can escape from the chain at several sites where they directly react with O2 and generate O2

(purple). Once formed, O2
 can either be detoxified by antioxidants or induce oxidative damage and apoptosis. Bz-423 inhibits complex V and
leads to proton accumulation in the intermembrane space (hyperpolarization), which causes increased electron escape from the ETC and O2

production. The effects of Bz-423 increase as rates of oxidative phosphorylation (OXPHOS) increase. (A) Resting lymphocytes and proliferating
cells in the bone marrow have low rates of OXPHOS, and thus little O2
 is produced by Bz-423. The little O2
 produced is efficiently detoxified
by the basal levels of antioxidants present in these cells and apoptosis is avoided. (B) Acutely activated lymphocytes have modestly increased rates
of OXPHOS and thus produce a modest amount of O2
 in response to Bz-423. However, the high levels of antioxidants in these cells effectively
detoxify the O2
 formed, and apoptosis is avoided. (C) Disease-causing lymphocytes have high rates of OXPHOS and produce large amounts of
O2
 in response to Bz-423. This O2
 cannot be detoxified due to antioxidant depletion and instead induces apoptosis.
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F1F0-ATPase (101). Bz-423 slows the flow of protons
through the F1F0-ATPase inducing a state 3-to-state 4 respi-
ratory transition that leads to hyperpolarization of Dwm,
O2
 production, and apoptosis (101–104) (Fig. 4). Consis-
tent with its mechanism, Bz-423 preferentially produces
ROS when mitochondria are actively respiring, whereas cel-
lular antioxidants protect against Bz-423-mediated O2
 pro-
duction and apoptosis (102, 103, 105, 106). As auto- and
allo-reactive lymphocytes have high levels of respiration and
depleted antioxidants, Bz-423 induces apoptosis in these
cells resulting in significant disease improvement in models
of lupus and GVHD (67, 102, 107) (Fig. 4). Importantly,
Bz-423 does not broadly induce lymphocyte apoptosis,
affect the number of T cells in treated mice, or alter the
normal immune response to challenge with foreign antigen.
This selectivity differentiates this class of immunomodulators
from agents used in the clinic or that are under develop-
ment.
The properties of Bz-423 have recently been studied in
several murine models of GVHD. Following bone marrow
transplant, two distinct sets of proliferating hematopoietic
cells coexist: Alloreactive donor T cells responding against
host antigens and HSCs and other progenitors repopulating
the host immune system. Although GVHD-causing T cells
upregulate OXPHOS and have low levels of antioxidants,
proliferating bone marrow cells upregulate glycolysis, have
low levels of OXPHOS, and maintain their antioxidant levels
(67). Treatment with Bz-423 increased ROS production and
apoptosis in GVHD-causing T cells but did not affect prolif-
erating bone marrow cells or bystander lymphocytes. Con-
sistent with these results, Bz-423 rescued mice from lethal
GVHD but did not adversely affect the repopulation of
donor thymocytes, granulocytes, or lymphocytes (67).
Concluding remarks
Although it has been known for the past several decades that
acutely activated lymphocytes generate their ATP using the
Warburg effect, particularly in vitro, emerging evidence dem-
onstrates that different lymphocyte subsets meet their meta-
bolic demands by differentially utilizing fundamental
metabolic pathways. The bioenergetic profile adopted by an
individual T cell appears to depend on a number of factors
including the chronicity of activation, the availability of
nutrients, and the cytokine environment in which a T cell
differentiates. On a molecular level, the regulation of T-cell
metabolism involves a network of molecular regulators
including AKT, HIF-1a, ERR-a, and Myc.
Recent studies have found that the metabolic phenotype
adopted by a particular T-cell subset facilitates its function.
The Myc-directed activation of glycolysis and glutaminolysis
facilitates biomass synthesis and proliferation early during
the activation of CD4+ and CD8+ T cells, whereas HIF-1a-
mediated glycolysis likely facilitates the hypoxic survival of
Th17 cells. By contrast, the FAO favored by Tregs and mem-
ory CD8+ T cells likely allows these cells to survive when
growth factors and glucose uptake have become limiting
and emphasizes that these cell types must survive long term
in the absence of proliferative signals to provide long-term
immunity and control inappropriate immune responses. In
the setting of GVHD, disease-causing T cells generate ATP
through OXPHOS and may use their limited glucose supply
to fuel proliferation rather than produce antioxidants, which
leaves them vulnerable to redox-induced apoptosis. The dif-
ferent metabolic phenotypes adopted by activated T-cell sub-
sets not only teach us about the function and biology of
these subsets but also provide the opportunity for the thera-
peutic manipulation of activated T-cell metabolism.
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